Mylan and Biocon have announced the UK launch of Semglee - an approved biosimilar of reference medicine insulin glargine.

Semglee is a once-daily, long-acting basal insulin indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above.

Around one in 17 people in the UK are thought to have diabetes, and the NHS currently spends around 10% of its entire budget on managing the disease, highlighting the huge drain on healthcare resources it presents.

“This has led to a growing need for more affordable treatment options for healthcare providers (HCPs) and their patients, to improve access to a broader range of treatment options for diabetes sufferers, which is critical to managing this growing healthcare challenge,” the firms note.

“Insulin glargine biosimilars play a key role in the challenges faced by the NHS and offer a better value option by being able to deliver increased affordability compared with the originator insulin glargine while still offering comparable safety, efficacy and tolerability,” noted Mylan UK country manager, Jean-Yves Brault.